药物释放型支架市场报告：趋势、预测和竞争分析（至 2031 年）

全球药物释放型支架市场前景看好，冠状动脉疾病和周边动脉疾病市场都存在机会。预计到 2031 年，全球药物释放型支架市场规模将达到 137 亿美元，2025 年至 2031 年的复合年增长率为 6.3%。该市场的主要驱动力是全球老年人口的成长和心血管疾病发生率的上升。

• Lucintel 表示，根据涂层类型，聚合物基涂层由于其公认的有效性和适应性，将在预测期内继续占据较大的市场份额。
• 从应用角度来看，由于全球冠状动脉疾病的盛行率不断上升，冠状动脉疾病预计将继续成为主要领域。
• 从地区来看，北美预计在预测期内仍将是最大的地区，因为它拥有发达的医疗保健基础设施和广泛采用的先进医疗技术。

药物释放型支架市场的策略性成长机会

DES 市场受到关键应用领域中各种策略机会的推动。识别并利用这些机会可以帮助您扩大市场占有率并改善患者的治疗效果。

• 扩展到新兴市场：由于心血管疾病盛行率上升和医疗保健投资增加，亚太地区和拉丁美洲等新兴市场代表着巨大的成长机会。扩大市场影响将有助于推动收益成长并增加我们先进支架技术的使用机会。
• 下一代支架的开发：对具有改进的药物输送系统、更薄的支柱和生物分解性材料的下一代 DES 的投资具有巨大的成长潜力。这些创新解决了当前的局限性，并提高了支架治疗的有效性和安全性，对临床医生和患者都具有吸引力。
• 数位健康技术的整合：将远端监控和数据分析等数位健康技术纳入 DES 治疗通讯协定可以改善患者管理和治疗结果。这些技术可以更好地追踪支架性能和患者依从性，从而实现更有效的治疗。
• 重视个人化医疗：对个​​人化医疗的日益重视为开发根据个别患者需求量身定制的 DES 解决方案创造了机会。利用基因和临床数据，製造商可以创建优化的药物配方和支架设计，以改善治疗效果。
• 影像技术的进步：将 OCT 和血管内超音波等先进的成像技术融入 DES 可以提高支架放置和部署的准确性。这些进步使得我们能够更好地评估血管状况并更准确地确定支架尺寸，从而改善患者的治疗效果。

DES 市场的策略成长机会由技术进步、市场扩张和个人化方法推动。相关人员可以利用这些机会来提高他们的市场地位并为改善患者照护做出贡献。

药物释放型支架市场驱动因素与挑战

DES 市场受到影响其成长轨迹的各种驱动因素​​和挑战的影响。技术进步、经济因素和监管问题在决定市场动态和影响相关人员的策略方面发挥关键作用。

推动药物释放型支架市场发展的因素包括：

• 技术进步：支架技术的创新，例如具有改进的药物传输系统和生物分解性材料的下一代 DES，正在推动市场成长。这些进步将提高支架的有效性和安全性，从而改善患者的治疗效果并提高采用率。
• 心血管疾病盛行率不断上升：全球心血管疾病盛行率不断上升是 DES 市场发展的主要驱动力。不断增加的患者数量将对有效的治疗方案产生巨大的需求，从而推动 DES 技术的发展。
• 监管支援和创新：简化监管流程和对创新医疗设备的支援有助于加快新 DES 技术的核准和进入市场。这样的法规环境鼓励持续的研究和发展并促进市场扩张。
• 医疗保健支出的增加：医疗保健支出的增加和对先进医疗技术的投资正在促进 DES 市场的成长。增加心血管护理资金使得尖端支架技术得以采用。
• 更重视个人化医疗：强调个人化医疗和客製化治疗方法正在推动 DES 的创新。根据个别患者情况量身订做的支架设计和药物治疗方案可改善治疗效果和市场需求。

药物释放型支架市场面临的挑战包括：

• 先进 DES高成本：先进 DES 技术高成本，可能限制其可近性和可负担性，尤其是在新兴市场。这项挑战将影响市场渗透率和采用率，尤其是在成本敏感的地区。
• 监管和报销障碍：复杂的监管要求和报销问题可能会对市场进入和扩张构成挑战。克服这些障碍需要大量的资源和专业知识，从而影响新 DES 技术的采用速度和简易性。
• 竞争和市场饱和：DES 製造商和产品数量的增加可能会导致市场饱和和竞争加剧。面对日益激烈的竞争，企业很难实现产品差异化并维持市场占有率。

技术进步和心血管疾病的增加等市场驱动因素正在推动 DES 市场向前发展。然而，持续成长和市场发展需要应对高成本和监管障碍等挑战。平衡这些因素对于塑造 DES 市场的未来至关重要。

目录

第一章执行摘要

2. 全球药物释放型支架市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球药物释放型支架市场趋势（2019-2024）及预测（2025-2031）
• 全球药物释放型支架市场（依涂层类型）
  • 聚合物基涂料
  • 无聚合物涂料
• 全球药物释放型支架市场（依应用）
  • 冠状动脉疾病
  • 周边动脉疾病

第四章区域市场趋势与预测分析（2019-2031）

• 全球药物释放型支架市场（按区域）
• 北美药物释放型支架市场
• 欧洲药物释放型支架市场
• 亚太药物释放型支架市场
• 世界其他地区的药物释放型支架市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球药物释放型支架市场成长机会（依涂层类型）
  • 全球药物释放型支架市场的成长机会（按应用）
  • 全球药物释放型支架市场各区域成长机会
• 全球药物释放型支架市场的新趋势
• 战略分析
  • 新产品开发
  • 全球药物释放型支架市场的产能扩张
  • 全球药物释放型支架市场的企业合併
  • 认证和许可

第七章主要企业简介

• Boston Scientific
• Medtronic
• Abbott Laboratories
• Biosensors
• Biotronik
• Lepu Medical Technology
• Terumo Medical
• Cook Medical
• Shandong JW Medical Systems
• B.Braun

The future of the global drug-eluting stent market looks promising, with opportunities in the coronary artery disease and peripheral artery disease markets. The global drug-eluting stent market is expected to reach an estimated $13.7 billion by 2031, with a CAGR of 6.3% from 2025 to 2031. The major drivers for this market are the increasing global elderly population and rising incidence of cardiovascular disorders.

• Lucintel forecasts that, within the coating type category market, polymer-based coatings will remain a larger segment over the forecast period due to their proven effectiveness and adaptability.
• Within the application category market, coronary artery disease will remain a larger segment due to the increasing global incidence of coronary artery disease.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of well-developed healthcare infrastructure and widespread adoption of advanced medical technologies in the region.

Gain valuable insights for your business decisions with our 150+ page report.

Emerging Trends in the Drug-Eluting Stent Market

Emerging trends in the DES market reflect advancements in technology, changing patient demographics, and evolving healthcare needs. These trends are influencing product development, market dynamics, and treatment outcomes, providing insights into the future of cardiovascular interventions.

• Biodegradable Stents: Biodegradable stents are gaining traction due to their ability to dissolve over time, reducing the risk of long-term complications and eliminating the need for permanent implants. These stents offer the advantage of restoring natural vessel function after degradation, which is beneficial for patients with complex cardiovascular conditions.
• Advanced Drug Delivery Systems: New DES technologies feature improved drug delivery systems that enhance the precision and efficacy of medication release. This includes the development of stents with controlled drug elution rates and novel drug combinations, which help reduce restenosis and improve overall treatment outcomes.
• Personalized Medicine: The trend toward personalized medicine in DES involves tailoring stent designs and drug formulations to individual patient profiles. Advances in genomics and diagnostics are allowing for more customized treatment approaches, potentially leading to better outcomes and reduced adverse events.
• Integration of Imaging Technologies: The integration of advanced imaging technologies, such as optical coherence tomography (OCT), is enhancing the precision of stent placement and deployment. These technologies provide detailed insights into vessel characteristics, allowing for more accurate stent sizing and placement.
• Regulatory Changes: Regulatory bodies are adopting more flexible and accelerated approval processes for innovative DES technologies. This includes streamlined pathways for clinical trials and faster market access, which encourage the development and availability of new stent options.

These emerging trends are reshaping the DES market by driving innovation, improving patient outcomes, and increasing market accessibility. As technology advances and regulatory landscapes evolve, the DES market will continue to grow and adapt to meet the needs of patients and healthcare providers.

Recent Developments in the Drug-Eluting Stent Market

Recent developments in the DES market are characterized by technological innovations, regulatory updates, and evolving healthcare needs. These changes are transforming the landscape of cardiovascular treatments, improving patient outcomes, and driving market growth.

• Introduction of Next-Generation Stents: Next-generation DES featuring thinner struts and improved drug coatings are now available. These advancements contribute to reduced restenosis rates and enhanced biocompatibility, leading to better long-term outcomes and patient satisfaction.
• Biodegradable Stent Technologies: The development of biodegradable stents, which gradually dissolve over time, has become a significant trend. These stents reduce the risk of chronic complications associated with permanent implants and restore natural vessel function, offering a promising alternative to traditional DES.
• Enhanced Drug Delivery Systems: Advances in drug delivery technologies, such as controlled-release mechanisms and novel drug formulations, are improving the efficacy of DES. These innovations ensure more precise and effective medication delivery, reducing the likelihood of restenosis and stent thrombosis.
• Increased Focus on Personalized Medicine: Personalized medicine is gaining traction, with DES being tailored to specific patient needs based on genetic and clinical profiles. This approach aims to optimize treatment outcomes by addressing individual variations in disease and response to therapy.
• Regulatory Changes and Market Access: Regulatory bodies are adopting more streamlined approval processes for innovative DES technologies. These changes facilitate quicker market entry for new stent designs and improve access to advanced treatment options for patients.

These recent developments are driving significant changes in the DES market, leading to improved patient outcomes and expanding market opportunities. As technology and regulations continue to evolve, the DES market is expected to grow and adapt to new challenges and opportunities.

Strategic Growth Opportunities for the Drug-Eluting Stent Market

The DES market is experiencing growth driven by various strategic opportunities in key applications. Identifying and leveraging these opportunities can lead to enhanced market presence and improved patient outcomes.

• Expansion into Emerging Markets: Emerging markets, such as Asia-Pacific and Latin America, present significant growth opportunities due to increasing cardiovascular disease prevalence and rising healthcare investments. Expanding market presence in these regions can drive revenue growth and increase access to advanced stent technologies.
• Development of Next-Generation Stents: Investment in next-generation DES with improved drug delivery systems, thinner struts, and biodegradable materials offers substantial growth potential. These innovations address current limitations and enhance the efficacy and safety of stent treatments, attracting both clinicians and patients.
• Integration of Digital Health Technologies: Incorporating digital health technologies, such as remote monitoring and data analytics, into DES treatment protocols can improve patient management and outcomes. These technologies enable better tracking of stent performance and patient compliance, leading to more effective treatments.
• Focus on Personalized Medicine: The growing emphasis on personalized medicine presents opportunities for developing customized DES solutions tailored to individual patient needs. By leveraging genetic and clinical data, manufacturers can create stents with optimized drug formulations and designs, enhancing treatment efficacy.
• Advancements in Imaging and Diagnostics: Integrating advanced imaging technologies, such as OCT and intravascular ultrasound, with DES can improve the precision of stent placement and deployment. These advancements allow for better assessment of vessel conditions and more accurate stent sizing, leading to improved patient outcomes.

Strategic growth opportunities in the DES market are driven by technological advancements, market expansion, and personalized approaches. By capitalizing on these opportunities, stakeholders can enhance their market position and contribute to improved patient care.

Drug-Eluting Stent Market Driver and Challenges

The DES market is shaped by a range of drivers and challenges that impact its growth trajectory. Technological advancements, economic factors, and regulatory issues play a crucial role in determining market dynamics and influencing stakeholder strategies.

The factors responsible for driving the drug-eluting stent market include:

• Technological Advancements: Innovations in stent technology, such as next-generation DES with improved drug delivery systems and biodegradable materials, are driving market growth. These advancements enhance the efficacy and safety of stents, leading to better patient outcomes and increased adoption.
• Growing Cardiovascular Disease Prevalence: The rising incidence of cardiovascular diseases globally is a significant driver for the DES market. Increasing patient numbers create a higher demand for effective treatment options, driving the growth of DES technologies.
• Regulatory Support and Innovation: Streamlined regulatory processes and support for innovative medical devices are facilitating faster approval and market entry for new DES technologies. This regulatory environment encourages ongoing research and development, driving market expansion.
• Rising Healthcare Expenditure: Increased healthcare spending and investment in advanced medical technologies are contributing to the growth of the DES market. Higher budgets for cardiovascular treatments enable the adoption of cutting-edge stent technologies.
• Growing Focus on Personalized Medicine: The emphasis on personalized medicine and tailored treatment approaches is driving innovation in DES. Customized stent designs and drug formulations based on individual patient profiles improve treatment outcomes and market demand.

Challenges in the drug-eluting stent market are:

• High Cost of Advanced DES: The high cost of advanced DES technologies can limit accessibility and affordability, particularly in emerging markets. This challenge affects market penetration and adoption rates, especially in cost-sensitive regions.
• Regulatory and Reimbursement Hurdles: Complex regulatory requirements and reimbursement issues can pose challenges for market entry and expansion. Navigating these hurdles requires significant resources and expertise, impacting the speed and ease of introducing new DES technologies.
• Competition and Market Saturation: The growing number of DES manufacturers and products can lead to market saturation and intensified competition. Differentiating products and maintaining market share amidst increasing competition can be challenging for companies.

Drivers such as technological advancements and growing cardiovascular disease prevalence are propelling the DES market forward. However, challenges like high costs and regulatory hurdles need to be addressed to ensure sustained growth and market development. Balancing these factors will be crucial for shaping the future of the DES market.

List of Drug-Eluting Stent Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, drug-eluting stent companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the drug-eluting stent companies profiled in this report include-

• Boston Scientific
• Medtronic
• Abbott Laboratories
• Biosensors
• Biotronik
• Lepu Medical Technology
• Terumo Medical
• Cook Medical
• Shandong JW Medical Systems
• B.Braun

Drug-Eluting Stent by Segment

The study includes a forecast for the global drug-eluting stent market by coating type, application, and region.

Drug-Eluting Stent Market by Coating Type [Analysis by Value from 2019 to 2031]:

• Polymer-Based Coating
• Polymer-Free Coating

Drug-Eluting Stent Market by Application [Analysis by Value from 2019 to 2031]:

• Coronary Artery Disease
• Peripheral Artery Disease

Drug-Eluting Stent Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Drug-Eluting Stent Market

The drug-eluting stent (DES) market has experienced significant advancements in recent years, driven by technological innovations, regulatory changes, and evolving patient needs. These developments are reshaping market dynamics across various countries. This summary provides an overview of recent trends and advancements in the DES market in the United States, China, Germany, India, and Japan.

• United States: In the U.S., recent advancements include the introduction of next-generation DES with enhanced biocompatibility and thinner struts, which reduce restenosis rates and improve patient outcomes. The FDA's streamlined approval process for innovative stent technologies has accelerated market entry. Additionally, there is a growing emphasis on personalized medicine, with stent designs tailored to specific patient demographics and conditions.
• China: China's DES market has seen rapid growth due to increasing cardiovascular disease prevalence and advancements in medical technology. Local manufacturers are investing heavily in research and development to produce cost-effective DES, leading to a rise in domestic production. Regulatory reforms have also facilitated faster approval of new DES technologies, boosting market growth.
• Germany: Germany remains a leader in the DES market in Europe, driven by its strong healthcare infrastructure and emphasis on advanced medical technologies. Recent developments include the adoption of biodegradable stents and innovations in drug delivery systems, which enhance the long-term safety and efficacy of DES. The German market also benefits from a robust reimbursement framework that supports the adoption of cutting-edge stent technologies.
• India: In India, the DES market is expanding due to increasing cardiovascular disease incidence and rising healthcare expenditure. Local and international companies are introducing affordable DES solutions to cater to the growing patient base. The Indian government's initiatives to improve healthcare access and infrastructure are also contributing to the market's growth.
• Japan: Japan's DES market is characterized by high adoption rates of advanced stent technologies and a focus on improving patient outcomes through innovation. Recent developments include the introduction of ultra-thin strut stents and advanced drug formulations. Japan's stringent regulatory standards ensure that only high-quality DES are approved, maintaining a high standard for patient care.

Features of the Global Drug-Eluting Stent Market

Market Size Estimates: Drug-eluting stent market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Drug-eluting stent market size by coating type, application, and region in terms of value ($B).

Regional Analysis: Drug-eluting stent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different coating types, applications, and regions for the drug-eluting stent market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the drug-eluting stent market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the drug-eluting stent market by coating type (polymer-based coating and polymer-free coating), application (coronary artery disease and peripheral artery disease), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Drug-Eluting Stent Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Drug-Eluting Stent Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Drug-Eluting Stent Market by Coating Type
  • 3.3.1: Polymer-Based Coating
  • 3.3.2: Polymer-Free Coating
• 3.4: Global Drug-Eluting Stent Market by Application
  • 3.4.1: Coronary Artery Disease
  • 3.4.2: Peripheral Artery Disease

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Drug-Eluting Stent Market by Region
• 4.2: North American Drug-Eluting Stent Market
  • 4.2.1: North American Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.2.2: North American Market by Application: Coronary Artery Disease and Peripheral Artery Disease
• 4.3: European Drug-Eluting Stent Market
  • 4.3.1: European Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.3.2: European Market by Application: Coronary Artery Disease and Peripheral Artery Disease
• 4.4: APAC Drug-Eluting Stent Market
  • 4.4.1: APAC Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.4.2: APAC Market by Application: Coronary Artery Disease and Peripheral Artery Disease
• 4.5: ROW Drug-Eluting Stent Market
  • 4.5.1: ROW Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.5.2: ROW Market by Application: Coronary Artery Disease and Peripheral Artery Disease

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Drug-Eluting Stent Market by Coating Type
  • 6.1.2: Growth Opportunities for the Global Drug-Eluting Stent Market by Application
  • 6.1.3: Growth Opportunities for the Global Drug-Eluting Stent Market by Region
• 6.2: Emerging Trends in the Global Drug-Eluting Stent Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Drug-Eluting Stent Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Drug-Eluting Stent Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Boston Scientific
• 7.2: Medtronic
• 7.3: Abbott Laboratories
• 7.4: Biosensors
• 7.5: Biotronik
• 7.6: Lepu Medical Technology
• 7.7: Terumo Medical
• 7.8: Cook Medical
• 7.9: Shandong JW Medical Systems
• 7.10: B.Braun